நோயாளிகள் உடன் எடுப்போசை மாரடைப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நோயாளிகள் உடன் எடுப்போசை மாரடைப்பு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நோயாளிகள் உடன் எடுப்போசை மாரடைப்பு Today - Breaking & Trending Today

Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction

Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Switzerland General , United States , United Kingdom , Harvard University , Boston Latin School , Martine Clozel , Andrewc Weiss , Coll Cardiol , Guy Braunstein , Jean Paul Clozel , Deepakl Bhatt , Mary Mooney , Cardiovascular Coordinating Center , Head Of Investor Relations Corporate Communications , Trinity College Dublin , United Kingdom Heart Attack Study Collaborative Group , Head Of Global Clinical Development At Idorsia , European Society Of Cardiology , Hospital Of The University Pennsylvania , Health Research Board , A Report From The American Heart Association , Member Of The Steering Committee , Idorsia Ltd , Professor Of Medicine At Harvard Medical School , Steering Committee , Study Group ,

Idorsia Pharmaceuticals Ltd: Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction

Idorsia Pharmaceuticals Ltd: Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction
Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs CEST
Allschwil, Switzerland - June 2
, 2021
Idorsia Ltd (SIX: IDIA) today announced the initiation of the Phase 3 registration study SOS-AMI to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia s P2Y
12 receptor antagonist, in suspected acute myocardial infarction (AMI).
An AMI, or heart attack, is a life-threatening condition that occurs when blood flow to the heart muscle (myocardium) is suddenly decreased or completely cut off by a blood clot in one or more of the coronary vessels. An AMI requires immediate treatment, as any delay in intervention can result in irreversible damage to the heart muscle and adverse clinical outcomes. According to the US Centers for Disease Control and Prevention, e ....

Switzerland General , United States , United Kingdom , Harvard University , Boston Latin School , Martine Clozel , Andrewc Weiss , Coll Cardiol , Guy Braunstein , Jean Paul Clozel , Deepakl Bhatt , Mary Mooney , Cardiovascular Coordinating Center , Head Of Investor Relations Corporate Communications , Trinity College Dublin , United Kingdom Heart Attack Study Collaborative Group , Head Of Global Clinical Development At Idorsia , European Society Of Cardiology , Hospital Of The University Pennsylvania , Health Research Board , A Report From The American Heart Association , Member Of The Steering Committee , Idorsia Ltd , Professor Of Medicine At Harvard Medical School , Steering Committee , Study Group ,

Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction

and Chair of the Steering Committee
for SOS-AMI, commented:
P2Y
12 receptor antagonists have been used in the treatment of millions of patients globally, and their safety and efficacy profiles are well established. Despite the success of chronic treatment with this class and other effective interventions, patients are still suffering recurrent heart attacks. The idea for patients to self-inject early in the onset of symptoms is truly innovative. The subcutaneous route of administration could overcome the onset delay observed with oral compounds from the same class.
To be effective, any antithrombotic treatment for use at the onset of AMI symptoms should be rapidly absorbed and potent, acting quickly to inhibit thrombus formation at an early stage. Inhibition should be reversed after a few hours to avoid interfering with later patient management decisions. It must also have an appropriate safety profile for use prior to formal diagnosis of AMI. Selatogrel has the ....

Switzerland General , United States , United Kingdom , Harvard University , Boston Latin School , Martine Clozel , Andrewc Weiss , Coll Cardiol , Guy Braunstein , Jean Paul Clozel , Deepakl Bhatt , Mary Mooney , Cardiovascular Coordinating Center , Head Of Investor Relations Corporate Communications , Trinity College Dublin , United Kingdom Heart Attack Study Collaborative Group , Head Of Global Clinical Development At Idorsia , European Society Of Cardiology , Hospital Of The University Pennsylvania , Health Research Board , A Report From The American Heart Association , Member Of The Steering Committee , Idorsia Ltd , Professor Of Medicine At Harvard Medical School , Steering Committee , Study Group ,

California Walnuts to Launch Global Marketing Initiative on March 3 with Coordinated "Power of 3" Events across the Globe

California Walnuts to Launch Global Marketing Initiative on March 3 with Coordinated Power of 3 Events across the Globe
The second annual international campaign educates consumers about walnuts unique nutrient composition and how a handful can improve overall wellness.
News provided by
Share this article
Share this article
FOLSOM, Calif., March 3, 2021 /PRNewswire/ The California Walnut Commission announced today the second annual Power of 3 global marketing campaign, which builds on the successful 2020 campaign. Power of 3 will launch on March 3
rd with a first-ever global event celebrated in the USA, Germany, India, Japan, South Korea, Spain, Turkey, the United Kingdom and the Middle East to showcase how they like to get their daily handful of walnuts. ....

State Of California , United States , United Kingdom , South Korea , Coll Cardiol , Pamela Graviet , Dieta Mediterr , California Department Of Food , Brain Health , Progress In Lipid Research , Heart Health , Journal Of The American College Cardiology , Office Of The , Program Discrimination Complaint Form , California Walnut Commission , Middle East , Senior Marketing Director , California Walnut , Lipid Research , American College , California Department , American Sign Language , Discrimination Complaint Form , Assistant Secretary , Civil Rights , Incident Adverse Events ,

California Walnuts to Launch Global Marketing Initiative on March 3 with Coordinated "Power of 3" Events across the Globe

California Walnuts to Launch Global Marketing Initiative on March 3 with Coordinated "Power of 3" Events across the Globe
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

State Of California , United States , United Kingdom , South Korea , Coll Cardiol , Pamela Graviet , Dieta Mediterr , California Department Of Food , Brain Health , Progress In Lipid Research , Heart Health , Journal Of The American College Cardiology , Office Of The , Program Discrimination Complaint Form , California Walnut Commission , Middle East , Senior Marketing Director , California Walnut , Lipid Research , American College , California Department , American Sign Language , Discrimination Complaint Form , Assistant Secretary , Civil Rights , Incident Adverse Events ,